Up to your usual tricks, Harvett? Rasul: The majority of...

Up to your usual tricks, Harvett?

Rasul: The majority of patients were previously treated with abiraterone/enzalutamide (69%) and docetaxel/cabazitaxel (67%)

LuPIN: All patients had received and failed two prior lines of therapy (chemotherapy and androgen signalling inhibitors) and most patients (29/32) had failed a third line of therapy (another chemotherapy) prior to entering the trial.

These trials have wildly different patient criteria. You should include a disclaimer with your posts, to acknowledge your unbalanced views.